BR112022017890A2 - Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina - Google Patents

Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina

Info

Publication number
BR112022017890A2
BR112022017890A2 BR112022017890A BR112022017890A BR112022017890A2 BR 112022017890 A2 BR112022017890 A2 BR 112022017890A2 BR 112022017890 A BR112022017890 A BR 112022017890A BR 112022017890 A BR112022017890 A BR 112022017890A BR 112022017890 A2 BR112022017890 A2 BR 112022017890A2
Authority
BR
Brazil
Prior art keywords
fragment
proadrenomedullin
seq
level
coronavirus
Prior art date
Application number
BR112022017890A
Other languages
English (en)
Inventor
Bergmann Andreas
Original Assignee
Sphingotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphingotec Gmbh filed Critical Sphingotec Gmbh
Publication of BR112022017890A2 publication Critical patent/BR112022017890A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

MÉTODOS PARA TRATAR A INFECÇÃO POR CORONAVÍRUS E LESÃO PULMONAR INDUZIDA POR INFLAMAÇÃO RESULTANTE. A presente invenção refere-se a método para (a) diagnosticar ou prever o risco de deterioração com risco de vida ou evento adverso ou (b) prognosticar a gravidade ou (c) prever ou monitorar o sucesso de uma terapia ou intervenção em um paciente infectado por um Coronavírus, o método compreendendo: determinar o nível de proadrenomedulina (SEQ ID NO 31) ou fragmento da mesma em uma amostra de fluido corporal do paciente; comparar o nível de proadrenomedulina ou fragmento da mesma a um limite predeterminado ou um nível prévio de proadrenomedulina ou fragmento da mesma, e; correlacionar o nível de proadrenomedulina ou fragmento da mesma com o risco de deterioração com risco de vida ou evento adverso, ou; correlacionar o nível de proadrenomedulina ou fragmento da mesma com a gravidade, ou; correlacionar o nível de proadrenomedulina ou fragmento da mesma com o sucesso de uma terapia ou intervenção, em que a proadrenomedulina ou fragmento da mesma é selecionada do grupo que consiste em PAMP (SEQ ID NO 32), MR-proADM (SEQ ID NO 33), ADM-NH2 (SEQ ID NO 20), ADM-Gly (SEQ ID NO 21) e CT-proADM (SEQ ID NO 34). A invenção também se refere a um anticorpo Antiadrenomedulina (ADM) ou fragmento de anticorpo anti-ADM ou suporte não-IgG anti-ADM para uso em terapia ou intervenção em um paciente infectado por um Coronavírus.
BR112022017890A 2020-03-16 2021-03-15 Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina BR112022017890A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062990171P 2020-03-16 2020-03-16
EP20163406 2020-03-16
US202063015102P 2020-04-24 2020-04-24
EP20179738 2020-06-12
US202163142370P 2021-01-27 2021-01-27
EP21153847 2021-01-27
PCT/EP2021/056575 WO2021185785A1 (en) 2020-03-16 2021-03-15 Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin

Publications (1)

Publication Number Publication Date
BR112022017890A2 true BR112022017890A2 (pt) 2022-11-01

Family

ID=74870833

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017890A BR112022017890A2 (pt) 2020-03-16 2021-03-15 Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina

Country Status (11)

Country Link
US (1) US20210285949A1 (pt)
EP (2) EP4121771A1 (pt)
JP (2) JP2023517717A (pt)
KR (1) KR20220154743A (pt)
CN (2) CN115917325A (pt)
AU (2) AU2021238592A1 (pt)
BR (1) BR112022017890A2 (pt)
CA (1) CA3112051A1 (pt)
IL (1) IL296385A (pt)
MX (2) MX2022011581A (pt)
WO (2) WO2021185785A1 (pt)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
DK1531791T3 (da) 2002-06-07 2010-11-01 Dyax Corp Forebyggelse og begrænsning af iskæmi
CA2543360A1 (en) 2003-10-24 2005-05-06 Joost A. Kolkman Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
WO2006032436A2 (en) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Use of microproteins as tryptase inhibitors
EP2231860B1 (en) 2007-12-19 2011-10-05 Affibody AB Polypeptide derived from protein a and able to bind pdgf
WO2010060748A1 (en) 2008-11-03 2010-06-03 Molecular Partners Ag Binding proteins inhibiting the vegf-a receptor interaction
US20110034580A1 (en) 2009-08-07 2011-02-10 ATI Industries, Inc. Carbon-Negative Bio-Plastic Furniture
CA2772162C (en) 2009-08-27 2018-05-22 Covagen Ag Anti-il-17a fynomers and medical uses thereof
US20120301393A1 (en) 2009-12-14 2012-11-29 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白
ES2494190T3 (es) 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
JP6193872B2 (ja) 2011-11-16 2017-09-06 アドレノメト アクチェンゲゼルシャフト 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
IL283215B1 (en) 2011-11-16 2024-01-01 Adrenomed Ag Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment and pharmaceutical preparations containing them
PT3553084T (pt) * 2011-11-16 2023-02-17 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou esqueleto não-ig anti-adm para prevenção ou redução de disfunção de órgãos ou insuficiência de órgãos num paciente possuindo uma doença crónica ou aguda ou condição aguda
ES2751492T3 (es) 2011-11-16 2020-03-31 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación
EP3082858B1 (en) * 2013-12-20 2021-01-27 AngioBiomed GmbH Adrenomedullin binder for use in therapy of cancer
CA3046850A1 (en) * 2016-12-16 2018-06-21 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP4159230A1 (en) * 2017-09-25 2023-04-05 AdrenoMed AG Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
US20210302440A1 (en) 2018-02-08 2021-09-30 Sphingotec Gmbh Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia
EP3608673A1 (en) * 2018-08-08 2020-02-12 B.R.A.H.M.S GmbH Pro-adm for prognosing the risk of a medical condition requiring hospitalization in patients with symptoms of infectious disease

Also Published As

Publication number Publication date
KR20220154743A (ko) 2022-11-22
CN115917325A (zh) 2023-04-04
EP4121772A1 (en) 2023-01-25
CA3112051A1 (en) 2021-09-16
US20210285949A1 (en) 2021-09-16
AU2021238592A1 (en) 2022-11-03
WO2021185785A1 (en) 2021-09-23
WO2021185784A1 (en) 2021-09-23
WO2021185784A4 (en) 2021-11-25
EP4121771A1 (en) 2023-01-25
JP2023518380A (ja) 2023-05-01
JP2023517717A (ja) 2023-04-26
MX2022011577A (es) 2022-10-18
WO2021185785A4 (en) 2021-11-11
MX2022011581A (es) 2022-10-18
CN115280154A (zh) 2022-11-01
IL296385A (en) 2022-11-01
AU2021238591A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
Napolitano et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study
BRPI0507442A (pt) métodos de diagnóstico e tratamento de pré-eclampsia ou eclampsia
CN111803645B (zh) S100a8\a9二聚体活性抑制剂在防治或诊断冠状病毒感染中的用途
Mandrioli et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy
Edetanlen et al. Comparison of outcomes in conservative versus surgical treatments for Ludwig’s angina
Bertrand et al. Rates of visual field loss before and after trabeculectomy
BR112023018220A2 (pt) Método para diagnóstico e tratamento de lesão tecidual profunda usando medições de umidade subepidérmica
BR112022017890A2 (pt) Proadrenomedulina ou fragmento da mesma em pacientes infectados com coronavírus e tratamentos com ligante contra adrenomedulina
Yang et al. RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation
Liu et al. Motor nerve conduction study and muscle strength in newly diagnosed POEMS syndrome
MD3774897T2 (ro) Metode și sisteme de selectare și tratare a pacienților cu boli inflamatorii
Yan et al. Utility of NSE, ProGRP and LDH in diagnosis and treatment in patients with small cell lung cancer
Dal Monte et al. Expression, localization, and functional coupling of the somatostatin receptor subtype 2 in a mouse model of oxygen-induced retinopathy
BR112022018235A2 (pt) Método de tratamento, método para tratar síndrome do desconforto respiratório agudo, método para inibir uma resposta de citocina em um paciente, método para tratar lesão renal aguda e método para tratar trombose
JP2016501889A5 (pt)
deGraft-Johnson et al. Safety and efficacy of single-dose preoperative intravenous dexamethasone on postoperative nausea and vomiting following breast surgery at Korle-Bu Teaching Hospital
Capone et al. Vitrectomy for refractory diabetic macular edema
Yasar et al. Can treatment with teicoplanin improve the prognosis of COVID‐19 patients?
Sun et al. Comparison of low and high doses of carvedilol on restoration of cardiac function and calcium‐handling proteins in rat failing heart
O'Sullivan et al. Decisive factors in the tolbutamide controversy
Ponzetto et al. Pathogenic strains of Helicobacter pylori in patients with hepatocellular carcinoma
BR112022017277A2 (pt) Dpp3 em pacientes infectados com coronavírus
Tatham et al. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B. 1.617. 2) in K18-hACE2 mice using an experimental design reflective of a treatment use case
KR101942649B1 (ko) 도축된 가금류의 처리 방법 및 처리 장치
JP2019516497A5 (pt)